.jpg)
Pfizer is set to acquire Seagen for $43 billion and create a new oncology division
13 Dec 2023
In a significant move, Pfizer has announced its anticipation of concluding the $43 billion deal to acquire cancer drug maker Seagen by 16 December 2023.
Moderna sues Pfizer-BioNtech for patent violation
02 Sep 2022
According to Moderna, Pfizer-BioNTech copied mRNA technology that Moderna had patented between 2010 and 2016, well before Covid-19 emerged in 2019
Pfizer eyes a market gatecrash as India’s Covid tally mounts
04 May 2021
US pharma giant Pfizer is trying to convince Indian authorities that there is no need for regulatory scrutiny for its corona virus vaccine that added $3.5 billion to its revenue in the first three months of this year, since it is approved by regulatory authorities in the US, Britain, Japan and the WHO, all of which India endorses
Pfizer to acquire cancer drug maker Array Biopharma for $10.6 bn
18 Jun 2019
Array’s Braftovi and Mektovi, launched last July for the deadliest form of skin cancer at a price of $22,000 per month, had sales of around $72 million over their first nine months, besides revenue from royalty and licensing deals
Stay ahead with Informachine News Trackers! Follow your selected sources, track business news with relevant keywords, and organize seamlessly using labels and bookmarks.
Get the business updates you need, fast, focused, and tailored just for you. Save time, stay informed, and never miss a beat!
Latest articles on Pfizer from Informachine
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
29 May 2026
Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and developme
Pfizer Advances Pivotal Pediatric Pneumococcal Vaccine Program Following Strong Positive Phase 2 Results
20 May 2026
Phase 2 data demonstrate robust immunogenicity, including enhanced response against serotype 3, alongside expanded protection across 25 serotypes; to achieve potential vaccine serotype coverage of 90%
European Commission Approves Pfizer’s HYMPAVZI for the Treatment of Adults and Adolescents with Hemophilia A or B With Inhibitors
14 May 2026
Approval in patients ages 12 and older based on Phase 3 data demonstrating superior bleed reduction to on-demand therapy, with continued benefit observed in open-label extension study HYMPAVZI is the
Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma
29 Apr 2026
Primary endpoint met at the interim analysis in MagnetisMM-5 trial demonstrating a statistically significant and clinically meaningful improvement in progression-free survival Safety was consistent wi
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
28 Apr 2026
Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in t
Pfizer Announces 2026 Shareholder Meeting Preliminary Results
24 Apr 2026
NEW YORK, April 23, 2026 – Pfizer Inc. (NYSE: PFE) today held its Annual Meeting of Shareholders. Preliminary results from the Annual Meeting indicate that the shareholders: reelected the company’s 12
Pfizer Declares Second-Quarter 2026 Dividend
24 Apr 2026
Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company’
Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026
22 Apr 2026
New evidence for established standard-of-care therapies, with updates for LORBRENA® in ALK-positive metastatic non ‑ small cell lung cancer and a BRAFTOVI® regimen in a type of BRAF-mutant colorectal
Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders
15 Apr 2026
Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT
